Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 559

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.

IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression

Open access
Sadik, Ahmed, Somarribas Patterson, Luis F., Öztürk, Selcen, Mohapatra, Soumya R., Panitz, Verena, Secker, Philipp F., Pfänder, Pauline, Loth, Stefanie, Salem, Heba, Prentzell, Mirja Tamara, Berdel, Bianca, Iskar, Murat, Faessler, Erik, Reuter, Friederike, Kirst, Isabelle, Kalter, Verena, Foerster, Kathrin I., Jäger, Evelyn, Guevara, Carina Ramallo, Sobeh, Mansour, Hielscher, Thomas, Poschet, Gernot, Reinhardt, Annekathrin, Hassel, Jessica C., Zapatka, Marc, Hahn, Udo, von Deimling, Andreas, Hopf, Carsten, Schlichting, Rita, Escher, Beate I., Burhenne, Jürgen, Haefeli, Walter E., Ishaque, Naveed, Böhme, Alexander, Schäuble, Sascha, Thedieck, Kathrin, Trump, Saskia, Seiffert, Martina, Opitz, Christiane A.·2020·Cell

Abstract

Aryl hydrocarbon receptor (AHR) activation by tryptophan (Trp) catabolites enhances tumor malignancy and suppresses anti-tumor immunity. The context specificity of AHR target genes has so far impeded systematic investigation of AHR activity and its upstream enzymes across human cancers. A pan-tissue AHR signature, derived by natural language processing, revealed that across 32 tumor entities, interleukin-4-induced-1 (IL4I1) associates more frequently with AHR activity than IDO1 or TDO2, hitherto recognized as the main Trp-catabolic enzymes. IL4I1 activates the AHR through the generation of indole metabolites and kynurenic acid. It associates with reduced survival in glioma patients, promotes cancer cell motility, and suppresses adaptive immunity, thereby enhancing the progression of chronic lymphocytic leukemia (CLL) in mice. Immune checkpoint blockade (ICB) induces IDO1 and IL4I1. As IDO1 inhibitors do not block IL4I1, IL4I1 may explain the failure of clinical studies combining ICB with IDO1 inhibition. Taken together, IL4I1 blockade opens new avenues for cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2020.07.038

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 134 references

Cited by

See all 559

Metadata

Authors
Sadik, A., Somarribas Patterson, L. F., Öztürk, S., Mohapatra, S. R., Panitz, V., Secker, P. F., Pfänder, P., Loth, S., Salem, H., Prentzell, M. T., Berdel, B., Iskar, M., Faessler, E., Reuter, F., Kirst, I., Kalter, V., Foerster, K. I., Jäger, E., Guevara, C. R., Sobeh, M., Hielscher, T., Poschet, G., Reinhardt, A., Hassel, J. C., Zapatka, M., Hahn, U., von Deimling, A., Hopf, C., Schlichting, R., Escher, B. I., Burhenne, J., Haefeli, W. E., Ishaque, N., Böhme, A., Schäuble, S., Thedieck, K., Trump, S., Seiffert, M., & Opitz, C. A.
Venue
Cell
Publisher
Elsevier BV
Published
2020-09
Volume
182
Issue
5
Pages
1252-1270.e34
ISSN
0092-8674 (ISSN-L)
OpenAlex
W3049896770
Cited by
559
References
134
FWCI
20.69
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. https://app.cochat.ai/papers/10.1016/j.cell.2020.07.038
The paper
Sadik, A., Somarribas Patterson, L. F., Öztürk, S., Mohapatra, S. R., Panitz, V., Secker, P. F., Pfänder, P., Loth, S., Salem, H., Prentzell, M. T., Berdel, B., Iskar, M., Faessler, E., Reuter, F., Kirst, I., Kalter, V., Foerster, K. I., Jäger, E., Guevara, C. R., . . . Opitz, C. A. (2020). IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell. https://doi.org/10.1016/j.cell.2020.07.038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.